News
ETNB
14.84
0.00%
0.00
Cantor Fitzgerald Suspends Overweight Rating on 89bio
Benzinga · 10/31/2025 13:47
89bio Completes Merger and Delists from Nasdaq
TipRanks · 10/30/2025 13:34
89Bio to Delist Shares from Nasdaq and Terminate SEC Registration
Reuters · 10/30/2025 13:04
Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress
Seeking Alpha · 10/30/2025 11:59
Roche Completes Acquisition of 89bio After Successful Tender Offer
Reuters · 10/30/2025 06:00
3 Investable Laggards In An Overbought Market
Seeking Alpha · 10/28/2025 21:13
Weekly Report: what happened at ETNB last week (1020-1024)?
Weekly Report · 10/27/2025 09:25
3 Biopharma Names I Am Buying After Avadel's Buyout
Seeking Alpha · 10/26/2025 13:45
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
NASDAQ · 10/23/2025 13:05
My Top 3 Pharma Stocks
Seeking Alpha · 10/20/2025 15:38
Weekly Report: what happened at ETNB last week (1013-1017)?
Weekly Report · 10/20/2025 09:24
Weekly Report: what happened at ETNB last week (1006-1010)?
Weekly Report · 10/13/2025 09:25
13D Filings
Barron‘s · 10/10/2025 22:20
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Seeking Alpha · 10/09/2025 15:33
Akero Therapeutics downgraded to Hold from Buy at Jefferies
TipRanks · 10/09/2025 15:20
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
NASDAQ · 10/06/2025 17:13
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
Barchart · 10/06/2025 16:10
Weekly Report: what happened at ETNB last week (0929-1003)?
Weekly Report · 10/06/2025 09:24
3 Reasons To Be Optimistic Around Biotech In Q4
Seeking Alpha · 10/05/2025 09:42
Swiss stocks - Factors to watch on October 2
Reuters · 10/02/2025 04:49
More
Webull provides a variety of real-time ETNB stock news. You can receive the latest news about 89Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ETNB
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.